Drug intelligence / Profile preview

AMB-104

Development stage: Preclinical
Lead developer: AmMax Bio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AMB-104 is an antibody-drug conjugate (ADC) developed by AmMax Bio for the treatment of cancer, specifically acute myeloid leukemia (AML) and solid tumors. Its mechanism of action is antagonism of the colony stimulating factor 1 receptor (CSF-1R), a target implicated in tumor-associated macrophage regulation and cancer progression. As a CSF-1R antagonist, AMB-104 aims to inhibit signaling pathways that support tumor growth and survival. The drug is currently in preclinical development[1][2][3][4].

Targets

CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on AMB-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMB-104.

Explore the full profile